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ABSTRACT 
Osteoporosis is a disease characterized by low bone mineral density and overall 
weakening of bone. It shows sex association, affecting post-menopausal women at higher 
rates than men. It is also is age specific, showing increased prevalence with aging in both 
sexes. Due to the increased mortality and severe disruptions in quality of life caused by 
osteoporosis-related fractures, the disease poses a serious public health concern (Sözen, 
Özışık, & Başaran, 2017). While osteoporosis is known to be related to environmental 
factors and associated lifestyle factors, recent genome-wide association studies (GWAS) 
have found dozens of loci associated with low bone mineral density and increased 
fracture risk, necessitating further study into specific causal genes (Sabik & Farber, 2017; 
Zheng, Spector, & Richards, 2011). Bone self-renewal, throughout life, is facilitated by 
resident mesenchymal stem cell (MSC) populations found within bone tissues, which are 
capable of osteogenic differentiation. Establishment of reliable cell culture methods for 
the growth and differentiation of bone marrow MSCs is a pre-requisite to carrying out 
comparative population-level studies of MSCs focused on assessing the interactions 
between underlying genetic and co-morbidity features that effect their osteogenic 
potential. Culture media is often supplemented with fetal bovine serum (FBS), containing 
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essential components that promote cell growth. However, use of FBS has led to issues in 
controllability and reproducibility of data from cultures supplemented with FBS because 
of its poorly-defined nature and variations in composition from sources of FBS. In this 
study, the efficacy of bone marrow-derived MSC (BMSC) cultures grown in a 
commercially available artificial media was compared to cells grown in media containing 
FBS, and their growth and osteogenic differentiation capacity were compared. 
Human MSCs were obtained from the acetabular reaming samples from 10 
patients undergoing total hip arthroplasty at Boston Medical Center. We processed the 
raw materials to remove tissue and adipose materials, and seeded using the loose cellular 
component of the bone marrow in media supplemented with FBS and commercially 
available serum-free media, Mesencult-ACF (Stem Cell Technologies, Vancouver, 
Canada). Adherent cell MSC populations were selected over a seven-day growth period.  
Osteogenic differentiation was initiated using supplementation with Dexamethasone, 
ascorbate, and b-glycerol phosphate. Cultured cells were grown in both media conditions 
for 21 days after osteogenesis was initiated. We examined cellular DNA content for cell 
growth, alkaline phosphatase (ALP) for osteogenic differentiation and calcium content 
for mineralization and terminal osteocyte differentiation.  
 We did not find significant differences between the groups for average DNA, 
ALP or calcium content (p=0.167, p=0.139, p=0.291). We did find significant differences 
within each subject between groups for nearly every subject and across all measurements. 
We did find significant differences in the DNA content and ALP content of the FBS 
supplemented media group between subjects (p=0.045, p=0.020). Findings suggest 
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Mesencult-ACF is a suitable alternative to media supplemented with FBS for promoting 
growth and differentiation of BMSCs.  
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INTRODUCTION 
 
Osteoporosis is the most common bone disease in humans, affecting people of all 
ages and sexes, but most predominantly postmenopausal females who are 
disproportionately affected by osteoporosis-related fractures and low bone mineral 
density (BMD) (Watts et al., 2010). Osteoporosis is characterized by deterioration of the 
microarchitecture of the bone and a loss of tissue, leading to an overall weakening of the 
bone (Figure 1). Bone fractures can cause significant disruptions in the quality of life of 
the affected individual due to chronic pain and disability, social isolation, and depression 
(Wang et al., 2016). Osteoporosis-related fractures have a mortality rate increase of 15-
20% within a year of the fracture and increase the risk of future fractures (Sözen et al., 
2017).  
Understanding the underlying pathology of osteoporosis is crucial for the 
development of more effective treatment options. A genetic basis for osteoporosis has 
been supported by the findings of dozens of loci associated with osteoporosis found in 
Genome-Wide Association Studies (GWAS) (Estrada et al., 2012). Such findings 
necessitate further research intent on locating specific genes within osteoblasts that 
contribute to low BMD and fracture risk in order to develop more targeted treatment 
options.  
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Figure 1. Osteoporotic Bone vs. Healthy Bone. The bone image on the left illustrates 
healthy trabecular bone and normal bone density. The image on the right demonstrates 
the deterioration of bone microarchitecture typical of osteoporotic bone (“Osteoporosis,” 
2014).  
 
 
1. Osteoporosis Management and Prevention 
1.1 Non-pharmacological approaches to Prevention and Treatment 
Current non-pharmacological strategies for managing osteoporosis are mainly 
preventative for the development of osteoporosis and for the occurrence of fractures. For 
reducing the risk of fractures, current nonpharmacological methods are aimed at 
maintaining or increasing BMD naturally (Gass & Dawson-Hughes, 2006). It is often 
recommended in common medical practice to those at risk or to those who have 
osteoporosis to engage in a healthy amount of physical activity that encourages bone 
mineralization, and to avoid any hazards or secondary causes that might lead to a 
fracture, such as excess alcohol intake, cigarette smoking or a living environment that 
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might make one more prone to falls (Watts et al., 2010). The efficacy of Vitamin D and 
Calcium as dietary supplements to prevent osteoporosis and related fractures is still 
disputed. In a meta-analysis of various trials, it was shown that Vitamin D and Calcium, 
given together as supplements, have been shown to be effective in reducing the risk of 
hip fractures. Given separately, they do not significantly reduce hip fracture risk (Murad 
et al., 2012).  Indeed, calcium supplementation on its own has been potentially related to 
a higher risk for myocardial infarction and other potential side effect risks are still unclear 
(Bauer, 2013).  
 
1.2. Pharmacological Approaches to Treatment 
Drugs most commonly used for the treatment of osteoporosis include 
bisphosphonates, Denosumab, estrogen replacement, and selective estrogen-receptor 
modulators (SERMs) , which generally either target inhibition of bone resorption and/or 
remodeling or work to increase and maintain bone formation (Black & Rosen, 2016; Gass 
& Dawson-Hughes, 2006). The use of antiresorptive drug therapy, such as with the use of 
bisphosphonates is typically the first line of treatment for post-menopausal women with 
osteoporosis (Pazianas & Abrahamsen, 2016). However, the use of certain 
bisphosphonates has been correlated to a rare but increased risk of atypical fracture and 
osteonecrosis of the jaw, amongst other side effects (Black & Rosen, 2016; Garg et al., 
2017; Shibahara, 2019). In post-menopausal patients with intolerance for 
bisphosphonates, Denosumab may be prescribed although there may be an increased risk 
for infections (Bonani et al., 2017). Estrogen replacement therapy and SERMs are not 
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first line therapies for post-menopausal women because their use increases risk for 
venous thromboembolic disorders, cardiac disease, and cancer (Pavone et al., 2017; 
Tabatabaei-Malazy, Salari, Khashayar, & Larijani, 2017).    
 
1.3.  Regenerative Medicine 
A relatively new area of interest for osteoporosis treatment is the use of stem-cell 
therapy. Promising regenerative clinical trials have already begun using autologous 
osteoblasts injections and bone marrow grafting in cases of long bone fracture healing 
(Garg et al., 2017). The use of stem cells for osteoporosis therapy has not yet been fully 
established due to potential issues concerning cell senescence, issues with long-term 
engraftment, and uncertainty of cell fate following transplantation—all of which must be 
further investigated (Antebi, Pelled, & Gazit, 2014; Phetfong et al., 2016).  
 
2. Pathogenesis of Osteoporosis 
 It is widely known that the dysregulation of cell signaling pathways responsible 
for upregulating or downregulating bone formation and/or bone resorption is a common 
feature of bone diseases such as osteoporosis. Osteoporosis, low BMD, and resulting 
fractures have been strongly correlated with heredity, therefore implying a genetic basis 
for the disease (Liu et al., 2012; Ralston & Crombrugghe, 2006; Ralston & Uitterlinden, 
2010; Zheng et al., 2011). The most recent GWAS have identified dozens of loci 
associated with variation in BMD and fracture risk (Estrada et al., 2012; Ralston & 
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Crombrugghe, 2006). Specific genes and direct causality have not yet been determined, 
but will be crucial for developing more targeted approaches to treatment in the future.  
 
3. Osteogenesis 
3.1. Mesenchymal Stem Cells 
 Mesenchymal stem cells (MSCs) are non-hematopoietic multipotent stem cells 
that are found in post-natal tissues and are capable of proliferating as well as 
differentiating into multiple types of committed cell lineages. Human adult MSCs are 
currently known to be capable of differentiating in vitro into adipocytes, osteoblasts, 
chondrocytes, neurons, and myocytes (Almalki & Agrawal, 2016; Chen et al., 2016; 
Czarnecka, Porowińska, Bajek, Hołysz, & Roszek, 2017; Jang, Cho, Park, & Jeong, 
2017) (Figure 2). MSCs can primarily be found in adults in bone marrow and adipose 
tissue, however other sources do exist (Chen et al., 2016; Hu et al., 2018; Ullah, 
Subbarao, & Rho, 2015).  
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Figure 2. Origins and Differentiation Potential of MSCs. MSCs can be derived from 
bone marrow, the umbilical cord, adipose tissue, the placenta, lungs, liver, and skin. 
MSCs are capable of expansion and self-renewal, demonstrating positive and negative 
markers for human and mouse MSCs. MSC differentiation potential includes adipocytes, 
osteoblasts, chondrocytes, neurons, and myocytes. (Chen et al., 2016) 
 
3.2. Osteoblasts 
Osteoblasts are cells derived from the MSC lineage and are responsible for 
building bone matrix and its mineralization, and give rise to osteocytes. Osteocytes are 
formed from osteoblasts that become embedded in bone matrix and are also involved in 
bone turnover (Aarden, Burger, & Nijweide, 1994). Bone remodeling is an ongoing 
process by which old bone is broken down and resorbed, and new bone is laid down in its 
place (Hadjidakis & Androulakis, 2006). Osteoblasts and osteocytes play a cooperative 
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role with osteoclasts—derived from hematopoietic stem cells—in bone remodeling, 
which requires constant communication and coordination between the two cell lineages 
(Lee, Guntur, Long, & Rosen, 2017; Rachner, Khosla, & Hofbauer, 2011) (Figure 3). 
Because of the important role osteoblasts have in bone modeling and formation, a 
comprehensive understanding of their activity and function has broader implications for 
understanding the mechanisms behind bone mineral density loss and osteoporosis.   
 
 
Figure 3. Prominent Cell Types Found in Bone Tissue. Osteogenic cells give rise to 
osteoblasts and osteocytes—two important cells involved in bone remodeling and 
maintenance respectively. Osteoclasts, which are directly involved in the bone resorption 
aspect of remodeling, are derived from hematopoietic cells (not pictured) found in bone 
marrow. (College, 2013).  
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4. Cell Culture 
 4.1. Bone Marrow-Derived Mesenchymal Stem Cells 
Mouse and Human BMSCs are an attractive option for cell culture due to their 
capacity to differentiate in vitro into osteoblasts and committed osteocytes when provided 
with certain osteogenic elements. Common cell culture practice indicates that BMSCs are 
typically grown using Dulbecco's modified Eagle's media (DMEM) supplemented with 
10% FBS, which constitutes the primary culture media pre-osteogenesis (Baghaei et al., 
2017; Ullah et al., 2015). To promote osteogenesis, the plates are further supplemented 
with ascorbate,  b-glycerol phosphate, and dexamethasone (Al-Saqi et al., 2014). 
Osteogenesis is indicated by the presence of positive cluster of differentiation (CD) 
markers, increased bone mineralization and alkaline phosphatase activity and the lack of 
negative CD markers (Hu et al., 2018; Ullah et al., 2015).  
 
 4.2. Fetal Bovine Serum  
The use of FBS in cell culture is widely applied, though in recent years has 
become less popular. FBS is made up of a poorly-defined mixture of proteins, hormones, 
growth factors, nutrients, and other components (Gstraunthaler, 2003). The nature of FBS 
is unreliable because of the potential differences in content and quality between sources 
as well as availability limitations. The use of FBS also raises ethical animal welfare 
concerns (van der Valk et al., 2018). Its inherent variability can affect the controllability 
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and reproducibility of data from cultures grown with FBS and allows for confounding 
variables within the data.  
Additionally, The use of FBS in MSC culture specifically used for the application 
of regenerative medicine has its own concerns. Instances of endotoxin contamination in 
FBS batches have been repeatedly reported (Even, Sandusky, & Barnard, 2006; Kirikae 
et al., 1997). One study reported that 20-50% of commercially available FBS was 
contaminated by virus (Wessman & Levings, 1999). Therefore, the increased risk for 
causing direct harm and/or immunological rejection poses a significant safety concern for 
its use in regenerative medicine or in any therapeutic application (Al-Saqi et al., 2014; 
Naskou et al., 2018). Thus, there is an increasing demand for an alternative method of 
cell culture that is serum-free.  
 
4.3. Serum-free Media 
The use of serum-free media is relatively new in cell culture practice. Its 
relevance and practical application was established in the early 1980’s (Barnes & Sato, 
1980). Currently, serum-free media formulations are available for nearly every cell type 
and the popularity and demand for animal-component free media has led to its 
commercialization. Though the advantages of using serum-free media include better 
reproducibility and controllability, in addition to the avoidance of animal welfare 
concerns and the accompanying safety concerns, its efficacy in comparison to FBS is still 
unclear, and may vary based on factors such as cell lineage or type.   
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4.4. Serum-free Media in Non-MSC Cell Culture  
One study (Piletz et al., 2018) compared the use of FBS to other xeno-free 
products while growing an endothelial cell line and a neuronal cell line. The results 
showed that the cell lines grown with FBS had a better proliferation rate and had 
comparatively less of an unwanted phenotype (presence of spheroids) in the neuronal 
population. They therefore concluded that FBS could not be replaced (Piletz et al., 2018).  
 
4.5. MSC Cultured in Serum-free and Serum-containing Media Comparison 
The rest of the literature available on the efficacy of alternatives to FBS in cell 
culture has been more positive, especially in the culture of MSCs.  
(Estrada et al., 2012) analyzed differences in cell number, viability, surface 
phenotype, and directed differentiation into adipogenic and osteogenic cell lines between 
groups of adipose-derived MSCs (ASCs) grown in synthetic, xeno-free media and those 
cultured with FBS. Their study showed that the MSCs grown in all groups that used 
commercially available synthetic media had significantly greater cell expansion rate than 
the FBS-containing groups and maintained a high viability, MSC surface phenotype, and 
capacity to differentiate (Estrada et al., 2012).  
The use of autologous human platelet lysate (HPL) is a xeno-free alternative to 
the use of FBS that has been shown to be an effective replacement for FBS in BMSC 
cultures (Azouna et al., 2012). The study aimed to induce the differentiation of BMSCs 
into four different lineages—osteogenic, adipogenic, chondrogenic and vascular smooth 
muscle—in HPL with and without FBS. The lines without FBS demonstrated a higher 
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rate of proliferation than those with FBS and successfully grew into all four lineages. The 
findings of the study suggest HPL to be a suitable alternative for FBS.   
In another study, ASCs and BMSCs grown in commercially available xeno-free 
media (Mesencult-XF) and media cultured with FBS (DMEM-FBS) were compared and 
evaluated for osteogenic and adipogenic potential. The results indicated that ASCs had a 
higher osteogenic differentiation potential in Mesencult-XF when compared to DMEM-
FBS, but showed nearly the same adipogenic differentiation potential in both groups. The 
BMSCs osteogenic differentiation potential was similar in both Mesncult-XF and 
DMEM-FBS groups, but had a lower adipogenic differentiation potential in the 
Mesencult-XF group when compared to the group cultured with FBS. The results also 
showed that the BMSCs in the Mesencult-XF group displayed a presence of cytoplasmic 
vacuoles and stained positive for b-galactosidase at passages 4 through 5. In contrast, the 
BMSCs in the DMEM-FBS cultured group did not contain vacuoles or stain positive for 
b-galactosidase. Because b-galactosidase staining indicates cell senescence, the study 
concluded that while the use of Mesencult-XF to culture ASCs is appropriate and 
potentially superior to the use of FBS, the use of Mesencult-XF with BMSCs is not well-
supported (Al-Saqi et al., 2014).  
In a similar study, ASCs and BMSCs were cultured with Mesencult-XF and with 
a-Minimum Essential Medium (a-MEM) containing FBS. The study measured 
proliferation over 10 passages, colony forming units (CFUs), and B-galactosidase 
staining. The results indicated that while both ASCs and BMSCs grown in Mesencult-XF 
has fewer CFUs than those grown in a-MEM-FBS, both cell lines grown in Mesencult-
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XF had an initially higher proliferation rate in early passages. However, in later passages, 
BMSCs cultured in Mesencult-XF showed a plateau in proliferation rate, and stained 
positive for b-galactosidase, indicating cell senescence. Contrastingly, BMSCs in serum-
containing media during later passages showed a continually increasing trend in 
proliferation and less intense staining for b-galactosidase. The same trends were not 
present in the ASC groups, which demonstrated higher proliferation rates in the 
Mesencult-XF group throughout all 10 passages. The results suggest that the use of 
Mesencult-XF may be more suitable for ASCs than BMSCs especially in later passages 
(Brohlin, Kelk, Wiberg, & Kingham, 2017).   
 
5. Study Goals 
This study compared the growth and differentiation capacity of BMSCs in 
traditional FBS-containing media to xeno-free Mesencult-ACF. The goal of this study 
was to establish a reliable method for the growth of BMSCs. The use of FBS in cell 
culture creates confounding variables for the data collection and interpretation. Therefore, 
a specific goal of this study was to determine whether the use of artificial, animal 
component free media would be sufficient at promoting osteogenesis in order for to 
substitute media cultured with FBS for the artificial media. Current literature generally 
supports the use of serum-free media with ASCs, however, the efficacy of certain serum-
free media with BMSCs for the long-term in comparison with FBS-containing media is 
unclear (Al-Saqi et al., 2014; Azouna et al., 2012; Brohlin et al., 2017).  Based on the 
available literature cited above, which supports the efficacy of Mesencult-XF usage in 
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BMSC cell lines during earlier passages, we hypothesized that BMSCs grown with 
Mesencult-ACF would promote faster growth and osteogenesis than its FBS-containing 
counterpart, given that the analysis would be of cells in their first passage. The 
knowledge gained in this study will inform the continuing practice of BMSC culture 
within a larger study that aims at identifying genes associated with osteoporosis.   
 
6. Specific Aims 
The aims of this study were:  
1. To compare the osteogenic capacity of BMSCs grown in animal component-free 
Mesencult-ACF and media supplemented with FBS  
2. Establish a reliable cell culture method for growth and differentiation of BMSCs in 
the future 
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METHODS 
 
1. Specimen Collection 
All human research was done under a Boston University School of Medicine 
Institutional Research Board Approved protocol: “Bone Tissues Repository”,  IRB 
Number: H-35199.  Subjects were consented by graduate students according to HIPAA 
guidelines before surgery. Acetabular reamings were collected from subjects (n=10; ages 
51—68; 4 males, 6 females) who underwent elective total hip arthroplasty as a treatment 
for osteoarthritis at Boston Medical Center in 2018 and 2019. The demographics of the 
subjects are described in Table 1. Exclusion criteria for patients include receiving 
chemotherapy, sickle cell, rheumatoid arthritis, bone metabolic modifying drugs for 
osteoporosis treatment, and other therapies known to modify bone. Reamings were 
obtained from the coring of the acetabulum and immediately placed on ice for transfer to 
the lab in the Orthopedic Surgery Department at Boston University.  
Acetabular reamings were immediately weighed upon retrieval from the operating 
room (Figure 4). The reamings were suspended in 120 mL warm, sterile PBS (Hyclone 
Laboratories, Inc., Logan, UT) in a sterile container and shaken. The solid components of 
the reamings were separated from the liquid PBS and cell-containing mixture using a 
metal, mesh strainer. The strained solid components were suspended in additional 100 
mL PBS, shaken, and strained again with the metal mesh strainer to eliminate residual 
bone chips. The strained liquid component—containing predominantly MSCs and red 
blood cells—was kept and processed further for this study. The solid components, made 
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up predominantly of bone chips and cartilage were kept and used for separation of bone 
and cartilage tissues in a separate project.   
 
Table 1. Subject Demographics 
Subject Number Sex Age Side of Arthroplasty Ethnicity Ethnicity 
203 F 59 L NA 
204 F 60 R White 
205 F 51 R White 
206 M 58 R White 
207 F 61 L White 
208 M 64 R African American 
209 M 68 L White 
210 M 53 R White 
211 F 54 L White 
212 F 55 R African American 
 
		 16 
 
Figure 4. Raw Acetabular Reamings. Pictured is the raw reamings received directly 
from the operating room before being processed.  
 
The remaining liquid—approximately 220 mL—was aliquoted evenly into 5, 50 
mL tubes (Corning Inc., Corning, NY) and centrifuged using a Centrifuge 5810 R 
(Eppendorf) at 1150 RPM for 7 minutes. The top 5 mL of the solution, containing a 
distinct layer of fat (Figure 5), was removed and discarded. Removing the top layer of fat 
after spinning down the solution was a step that was developed in order to reduce total 
time and amount of filters needed to complete the subsequent filtration steps. Each tube 
was then filtered sequentially through a 70-micron and then a 40-micron filter (Corning 
Inc., Corning, NY) once.  
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After filtration, the sample were centrifuged again at 1150 RPM for 7 minutes. 
The supernatant was removed and discarded from each tube, and 10 mL of PBS was 
added to each tube. The cells were resuspended, then combined into two tubes. The two 
tubes were centrifuged again at 1150 RPM for 7 minutes. The supernatant was removed 
and discarded from both tubes, and 10 mL of PBS was added to both tubes and 
resuspended. The solution was then diluted in PBS in a 1:100 ratio. The cells were 
counted from the dilute solution using a hemocytometer.  
 
 
Figure 5. Fat Layer After Straining. One sample of the cell-containing mixture after 
being strained with metal mesh strainer twice and centrifuged. Arrow pointing to the 
layer of fat which was removed and discarded before subsequent steps.   
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2. Cell Culture 
2.1. Seeding  
The cells were seeded at 2.66 x106 cells/well using 24-well cell culture plates 
(Corning Inc., Corning, NY) and grown in a humidified incubator (37° C, 5% CO2). The 
cells were seeded into two experimental groups—Control Media (CM) and Artificial 
Media (AFM) (see Table 2). Each group was composed of into 2, 24-well plates. One 
plate was used for the Alkaline Phosphatase (ALP) and Alizarin Red S (ARS) assays, and 
the other plate was used for the DNA assay. The AFM plates were pre-treated before 
seeding with Animal Component-Free Cell Attachment Substrate (Stem Cell 
Technologies, Vancouver, Canada) diluted 1 in 150 with PBS. The plates were filled with  
0.25 mL per well and incubated at room temperature for at least two hours prior to 
plating. The dishes were then washed with PBS and seeded. 
The cells that were not used for this study were frozen at 10x106 cells/mL of  90% 
FBS (Atlanta Biologicals, Inc., Flowery Branch, GA) and 10% Dimethyl Sulfide 
(DMSO) (American Bioanalytical, Canton, MA). Cells were frozen slowly and stored 
using the Mr. Frosty Freezing Container (Thermo Fischer Scientific, Waltham, MA) at -
80°C. 
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2.2. Pre-Osteogenic Media  
CM comprises Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher 
Scientific, Waltham, MA) 10% FBS and 10% penicillin/streptomycin antibiotic (1x104 
U/mL) (Thermo Fischer Scientific, Waltham, MA) for the first 6 days of culture.  
AFM comprises Mesencult-ACF™ Plus Medium (Stem Cell Technologies, 
Vancouver, Canada) with 0.2% MesenCult™-ACF Plus 500X Supplement and 1% L-
glutamine (Thermo Fischer Scientific, Waltham, MA). Four days after seeding, half of 
the respective pre-osteoinductive basal media volume was changed for both groups. 
 
2.3. Osteogenic Media 
At six days after seeding, cells in the CM group received a full media change from 
DMEM to Minimum Essential Medium-alpha (a-MEM) (Thermo Fischer Scientific, 
Waltham, MA) with 10% FBS and 1% penicillin/streptomycin antibiotic. At six days, 
AFM  group did not receive a change in basal media. At six days, both groups received 
12.5µg/ml L-Ascorbate (Sigma-Aldrich Corporation, St. Louis, MO), 1.0x10-8 M 
Dexamethasone, and 8µl/ml (8mM) b-glycerol phosphate (bGP) (Sigma-Aldrich 
Corporation, St. Louis, MO) to promote osteogenesis. The media was changed every 48 
hours after day six for both experimental groups. All plates within each group were fixed 
after 21 days of incubation in osteogenic media and subsequent experiments were 
performed.  
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Table 2. Culture Medium Conditions. Both groups were cultured in basal media for 6 
days post-seeding, and in osteogenic media for the following 21 days. The osteogenic 
supplements (L-Ascorbate, Dexamethasone, and b-glycerol phosphate) and 
concentrations were identical for both groups. Groups varied in amount of FBS, 
Penicillin/Streptomycin, L-Glutamine, and MesenCult™-ACF Plus 500X Supplement. 
 
CM Basal 
(Day 1-6) 
CM 
Osteoinductive 
(Day 7-28) 
AFM Basal 
(Day 1-6) 
AFM 
Osteoinductive 
(Day 7-28) 
Base DMEM1 a-MEM1 
Mesencult™-
ACF2 
Mesencult™-
ACF2 
Fetal Bovine 
Serum3 
10% 10% N/A N/A 
Penicillin/ 
Streptomycin1 
10% 1% N/A N/A 
L-glutamine1 N/A N/A 1% 1% 
MesenCult™-
ACF Plus 500X 
Supplement2 
N/A N/A 0.2% 0.2% 
L-Ascorbate4 N/A 12.5µg/mL N/A 12.5µg/mL 
Dexamethasone N/A 1.0x10-8 M N/A 1.0x10-8 M 
b-glycerol 
phosphate 
N/A 8mM N/A 8mM 
1Thermo Fischer Scientific, 2Stem Cell Technologies, 3Atlanta Biologicals, 4Sigma-
Aldrich  
 
3. Assays 
Twenty-one days after osteogenic media introduction, cells were fixed in 
preparation for an Alkaline Phosphatase Assay, Alizarin Red S Quantification Assay, and 
PicoGreen DNA Assay. One 24-well plate was used to run both the ALP and ARS 
Quantification Assay. The PicoGreen DNA Assay was run on a separate 24-well plate.  
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3.1. Alkaline Phosphatase Assay 
Measuring ALP is one of the most common methods for detecting bone 
mineralization. It is a widely utilized biomarker used to indicate osteoblast activity (Anh, 
Dimai, Hall, & Farley, 1998; Garnero & Delmas, 1998; Golub, Harrison, Taylor, 
Camper, & Shapiro, 1992; Sabokbar, Millett, Myer, & Rushton, 1994). In this study, we 
measured ALP at twenty-one days after osteogenic media introduction using one 24-well 
plate from each group. The respective mediums were removed from each plate, which 
were then washed 3 times with PBS at room temperature. The plates were fixed with 250 
µl 2% Paraformaldehyde (PFA) (Sigma-Aldrich Corporation, St. Louis, MO) for 20 
minutes at room temperature. The wells were then washed twice with distilled water, 
sealed in Parafilm (Sigma-Aldrich Corporation, St. Louis, MO) to prevent evaporation, 
and stored at 20°C. For assay 450 µL of a buffer solution made up of 0.1M glycine 
(Sigma-Aldrich Corporation, St. Louis, MO) and 1mM magnesium chloride (Sigma-
Aldrich Corporation, St. Louis, MO), and 50 µL of 54mM 4-p-Nitrophenyl Phosphate 
(pNPP) (Sigma-Aldrich Corporation, St. Louis, MO) were added per well and then 
incubated in the dark for 30 minutes at 24oC. 500 µL of the solution from each well was 
transferred into 1.5 mL tubes (Eppendorf) containing 500µL 3M NaOH (Thermo Fischer 
Scientific, Waltham, MA) and mixed. A blank was also prepared with 450µL of buffer, 
50µL pNPP, and 500µL 3M NaOH. 100µL of the solution was aliquoted in duplicates 
from each well onto a 96-well plate. The colorimetric assay was run on a BioTek Synergy 
2 Multi-mode Microplate Reader (BioTek Instruments Inc., Winooski, VT) at 405nm 
absorbance.  
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3.2. Alizarin Red S Calcium Quantification Assay 
After the ALP assay, the excess pNPP and buffer solution was removed from the 
plates, which were then washed once with distilled water to be used for the ARS Assay. 
The ARS dye, which binds to calcium, is a good indicator for the amount of 
mineralization that has occurred, which implies cell differentiation (Gregory, Grady 
Gunn, Peister, & Prockop, 2004). 450 µL of ARS dye (Millipore, Temecula, CA) was 
added to each well and then incubated for 30 minutes at room temperature. The dye was 
removed and washed four times with distilled water. In between each wash, the plates 
were put on a rotary shaker for 5 minutes. After the fourth wash, distilled water was 
added to each well to prevent drying. Pictures were taken at this step to document the 
appearance of nodules on the wells.  
After taking pictures, the excess distilled water was removed. 200 µL of 10% 
acetic acid was added to each well and incubated for 30 minutes at room temperature on a 
shaker. The cells were scraped from the plates using the end of a 1000 µL pipette tip and 
the entire contents of each well were transferred to a 1.5 mL tube (Eppendorf). The tubes 
were vortexed for 30 seconds and then heated to 85°C for 10 minutes. After heating, the 
tubes were transferred to ice for 5 minutes and then centrifuged at 14,000 RPM for 20 
minutes. 175 µL of the supernatant was removed and transferred to a new 1.5 mL tube 
and then neutralized with 66 µL of 10% Ammonium Hydroxide (Sigma-Aldrich Inc., 
Saint Louis, MO). 100 µL of the solution was aliquoted twice from each well onto a 96-
well plate. The colorimetric assay was run using BioTek Synergy 2 Multi-mode 
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Microplate Reader at 405 nm absorbance. The blank was made up of 175 µL of acetic 
acid and 66 µL of ammonium hydroxide.  
 
3.3. DNA Extraction and Assay 
Relative DNA concentrations of the cells growing in the 24-well plates was 
determined using Quant-iT™ PicoGreen™ dsDNA Assay Kit (Thermo Fisher Scientific, 
Waltham, MA). The plates used for this assay were separate from those used for the ALP 
and ARS assays. The DNA extraction buffer was made using 4M Guanidine HCl (Sigma-
Aldrich Inc., Saint Louis, MO), 1% Triton X-100 Lysis Buffer (Sigma-Aldrich Inc., Saint 
Louis, MO), and 10mM 1X TE Buffer (pH 7.4) (Life Technologies Inc., Beverly, MA). 
The plates were first washed once with PBS, and 100 µL of the extraction buffer was 
used per well. The plates were incubated at room temperate for 30 minutes on a shaker. 
The cells were then scraped using a 1000 µL pipette tip and were transferred with the 
extraction buffer into a 1.5 mL tube (Eppendorf). 100 µL of Ultrapure (RNase- and 
DNase-free) Distilled Water (Thermo Fisher Scientific, Waltham, MA) was then added 
and the total extraction solution was stored at -80°C. 
The cells, extraction buffer, and ultrapure water were thawed, then diluted 1:1 in 
1X TE buffer. 100 µL of the diluted sample was aliquoted into a 96-well plate. The 
PicoGreen reagent was diluted 200X in 1X TE, and 100µL of the dilution was added to 
each well containing the sample, covered with foil, and incubated at room temperature 
for two to five minutes on a shaker. A standard curve was also prepared. The plates were 
read using the BioTek Synergy 2 Multi-mode Microplate Reader, measuring excitation 
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was at a wavelength of 485 nm and a bandwidth of 20 nm., and emission at a wavelength 
of 530 nm and a bandwidth of 25 nm.  
 
4. Statistical Analysis 
There were a total of 10 subjects used for this project, however, two (subjects 203 
and 208) were excluded from the analysis due to technical error. Therefore, 8 subjects 
were used to measure outcomes. Means and standard deviations of ALP and ARS 
measurement values were normalized to DNA concentration. Outcomes were compared 
among the different conditions using a Paired Sample t-test to determine the differences 
between media supplemented with FBS and serum-free media at a significance of a = 
0.05. For each condition, we examined differences between the total group averages, 
groups within each subject as well as between subjects for both groups.  
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RESULTS 
 
1. DNA Quantification  
DNA concentration was measured using a PicoGreen fluorescence assay. Average 
DNA concentrations were determined for each group within each subject, and were 
normalized to a standard curve for every experiment. The total average DNA 
concentration for all AFM groups was not significantly different than the total average 
DNA concentration for all CM groups (p=0.167) (Figure 6). However, we did find 
significant differences in DNA concentrations between groups of the same subject for 
every subject (Figure 7). The AFM groups in subjects 204, 205, and 207 had a 
significantly higher DNA concentrations than their respective CM groups (p=0.002; 
p<0.001; p=0.014) . Subjects 206, 209, 210, 211, and 212 had significantly higher DNA 
concentrations in their CM groups than in the AFM groups (p=0.048; p<0.001; p<0.001; 
p<0.001; p=0.018) (Figure 7). There were no significant differences in DNA content 
between the AFM groups between subjects when normalized to CM (p=0.352) (Figure 8) 
However, there were significant differences between the DNA contents of the CM groups 
between subjects when normalized to AFM (p=0.045) (Figure 8).   
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Figure 6. Total Average Cellular DNA Content of Groups. DNA content was 
quantified using a PicoGreen fluorescence assay measured at 485nm/20nm excitation and 
530nm/25nm emission. All DNA fluorescence values were normalized to a standard 
curve. Individual average DNA concentrations for both CM and AFM groups from each 
subject were combined with all subjects into two total group averages. Total average 
DNA concentration did not significantly differ between groups (p=0.167).  
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Figure 7. Average Cellular DNA Concentrations of Subjects. DNA content was 
quantified using a PicoGreen fluorescence assay measured at 485nm/20nm excitation and 
530nm/25nm emission. All DNA fluorescence values were normalized to a standard 
curve. The graph demonstrates individual average DNA concentrations for both groups in 
each subject. All subjects showed significantly different average DNA concentrations 
between both groups. (*p<0.05, **p<0.01,***p<0.001). 
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Figure 8. Differences in DNA Content Between Subjects. AFM DNA values were 
scaled to the same subject’s corresponding CM DNA value. The graph represents AFM 
DNA values for every subject as a factor of its CM value. There was no significant 
difference between the DNA content of AFM groups between subjects (p=0.352). We 
found an overall significant difference in CM DNA content between subjects (p=0.045). 
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However, subject 205 had a significantly higher average ALP content in their AFM group 
than in their CM group (p<0.001) (Figure 10). Between subjects, average ALP content 
was not significantly different in the AFM groups (p=0.2854) (Figure 11), however, there 
were significant differences between subjects in the CM groups (p=0.020) (Figure 11). 
 
 
Figure 9. Average ALP Concentrations of Groups. All ALP absorbance values were 
normalized to controls and DNA content. Individual average ALP concentrations for each 
subject’s CM and AFM groups were combined with all subjects into two total group 
averages. Total average ALP content did not significantly differ between groups 
(p=0.139).  
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Figure 10. Average ALP Concentrations of Subjects. ALP was quantified using pNPP 
as a substrate in a colorimetric assay. ALP absorbance values were normalized to controls 
and DNA concentration. All subjects except for subject 207 showed significantly 
different ALP content between its two groups. (*p<0.05, **p<0.01,***p<0.001). 
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Figure 11. Differences in ALP Content Between Subjects. AFM ALP values were 
scaled to the same subject’s corresponding CM value. The graph represents AFM ALP 
values for every subject as a factor of its CM value. There was no significant difference 
between the ALP content of AFM groups between subjects (p= 0.353). There was a 
significant difference between the ALP content of CM groups between subjects (p= 
0.020).  
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p=0.001). Subject 205 had an approaching significant difference between its CM and 
AFM group (p=0.055) (Figure 13). Within the same group, ARS content was not 
significantly different between subjects for either the CM group or AFM group (p=0.185; 
p=0.107) (Figure 14).  
 
 
Figure 12. Average ARS Concentrations of Groups. All calcium absorbance values 
were normalized to controls and then normalized to DNA concentration. . Individual 
average ARS concentrations for each subject’s CM and AFM groups were combined with 
all subjects into two total group averages.  Total average ARS concentration did not 
significantly differ between groups (p=0.291).  
 
 
-0.0002
-0.0001
0
0.0001
0.0002
0.0003
0.0004
0.0005
0.0006
0.0007
0.0008
CM AFM
A
bs
or
ba
nc
e 
(4
05
nm
)
Groups
Total Average ARS Concentration Normalized to DNA
		 33 
 
Figure 13. Average ARS Concentrations of Subjects. Calcium was quantified using an 
Alizarin Red S stain in a colorimetric assay. ARS absorbance values were normalized to 
controls and DNA concentration. All subjects except for subjects 205 and 206 showed 
significantly different ALP content between its groups. (*p<0.05, **p<0.01,***p<0.001, 
†approaching significance).  
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Figure 14. Differences in ARS Concentration Between Subjects. AFM ARS values 
were scaled to the same subject’s corresponding CM value. The graph represents AFM 
ARS values for every subject as a factor of its CM value. There was no significant 
difference between the ARS content of AFM groups between subjects (p= 0.107). There 
was no significant difference between the calcium content of AFM groups between 
subjects (p= 0.185).  
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DISCUSSION 
 
This study investigated differences in osteogenic potential between BMSCs 
grown in animal component-free, artificial media (Mesencult-ACF) and media 
supplemented with fetal bovine serum. The specific goal of this study was to determine 
whether the artificial media would support growth and osteogenesis comparably to media 
supplemented with FBS. Human BMSCs were collected via the acetabular reamings of 
subjects undergoing total hip replacement surgery. Cells from each subject were grown in 
two separate conditions—Artificial Media (AFM) (Mesencult-ACF) and Control Media 
(CM) (a-MEM supplemented with FBS). We specifically focused on measuring DNA 
concentration, mineralization, and alkaline phosphatase concentration after 21 days of 
culture in osteogenic media.  
 
1. Cell Growth 
 To compare growth of the cells in both conditions, we measured average DNA 
concentration using a PicoGreen DNA assay kit. We found that the average cellular DNA 
concentration did not differ between the two conditions, which suggests that one media 
condition does not promote cell growth more than the other. In light of this, we might 
expect that within each subject, there would be no differences in DNA content between 
the two groups. Surprisingly, every subject showed a significant difference between its 
own CM and AFM group—three out of eight subjects had a higher average DNA 
concentration in the AFM group and 5 out of 8 had a higher average DNA concentration 
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in the CM group. So far, it is unclear as to why it appears that the cells of each individual 
subject exhibit more growth in one media condition than in the other, however there is no 
advantage between the CM and the AFM. 
DNA concentration was not significantly different between the AFM groups of all 
subjects when normalized to CM. In contrast, we did find a significant difference 
between the DNA concentrations of CM groups of all subjects. Although the FBS we 
used for these experiments was from the same source, the lack of consistency in growth 
across subjects for the CM group may be due to the presence of FBS. This would support 
the current literature which reports issues with the controllability of FBS (Gstraunthaler, 
2003). This finding also suggests that BMSCs grown in Mesencult-ACF group may have 
more consistent results in regards to growth when compared to media supplemented with 
FBS.  
  
2. Differentiation  
2.1 Alkaline Phosphatase 
 Alkaline Phosphatase is a key biomarker that is present in bone mineral and is 
expressed by osteoblasts (Atkins, Findlay, Anderson, & Morris, 2011). Our ALP assay 
experiment, which measured the concentration of secreted ALP in our samples, will 
provide insight on the degree of differentiation that occurred in our cultures.  
 Although we did not find a significant difference in average ALP content between 
the two media conditions, the results showed that six of the eight subjects had higher 
ALP values in the CM group compared to the AFM group. Only one subject had higher 
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ALP concentration in the AFM group than the CM group, and one subject did not have a 
significant difference between the two groups. Similar to the results for the DNA assay in 
relation to growth, it appears that individual subjects’ BMSC’s may promote osteogenesis 
more in one media condition than in the other. One explanation for the significantly 
lower ALP values in many of the AFM groups could be that the cells in those groups may 
actually be more differentiated than their CM counterparts. Though ALP is an early 
biomarker for osteogenic differentiation, levels of ALP tend to decrease over time after 
osteogenesis has begun. It is believed that this is due to negative regulation by the 
presence of calcium in bone mineral (Anh et al., 1998). If this were the case in our 
experiment, it would suggest that the cells of subjects with lower AFM ALP values may 
have differentiated faster and further than those in the CM group.  
 The lack of a difference between AFM groups’ ALP values across subjects in 
light of the significant difference between that of the CM groups suggests that the groups 
supplemented with FBS may not be as controllable as the groups grown in Mesencult-
ACF. Such findings are consistent with those demonstrated in the DNA assay and with 
current literature (Gstraunthaler, 2003).  
 
2.2 Calcium  
Similar to the findings of both ALP and DNA assays, the ARS assay results 
showed no significant difference in average calcium content between the FBS 
supplemented group and the group grown in Mesencult-ACF. All but one subject had 
significantly higher values in one group when compared to the other, indicating that each 
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subject’s cells tend to promote better mineralization in a particular group, though the 
preferred group varied from subject to subject. Because there were no significant 
differences in calcium content between the same group of different subjects, the data 
suggests that both media promoted mineralization comparably. 
 Our original aim was to determine whether Mesencult-ACF promoted growth and 
differentiation of BMSCs more successfully than media supplemented with FBS. The 
findings suggest there was no significant difference between the two culture conditions in 
respect to growth or osteogenesis. However, using FBS introduces confounders that 
would otherwise be eliminated using Mesencult-ACF, due to being animal-component 
free. In our own findings, there were significant differences among DNA and ALP values 
for CM between subjects, indicating a possible lack of controllability. Therefore, there 
may be an advantage to using Mesencult-ACF if the overall promotion of growth 
osteogenesis is not significantly different from media supplemented with FBS and if it is 
more controllable and eliminates an otherwise confounding variable.   
 
3. Limitations  
There were several limitations of this study including the sample size. Because 
our study involved human subjects, there is greater variability between subjects, and is 
therefore more difficult to observe a significant result with a small sample size.  Although 
we excluded subjects with certain known medical conditions and those on certain 
medications, the amount of unknown variables were still high. For example, the 
acetabular reamings that are collected vary in volume, content, and depth of the 
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acetabular coring for each patient. Therefore, the amount of BMSCs initially seeded may 
vary from subject to subject. Another limitation occurs at the seeding step, where we did 
not employ any method for only selecting BMSCs for seeding. The cell count used for 
seeding included red blood cells and other cells that are free in bone marrow. In the 
future, it may be preferable to introduce a method other than the conditioned expansion 
media that will allow us to only select BMSCs for seeding using a cell sorting method, 
such as density gradient separation (Juopperi et al., 2007). 
 Additionally, for our experiments, we used two separate 24-well plates for the 
DNA assay and the ALP and ARS assays. Using two separate plates requires the 
assumption that the DNA, ALP and calcium content on both plates were identical. 
Because we normalized the ALP and ARS values to DNA, it is ideal that the DNA 
content is derived from the same cells used to run the ALP and ARS assay. For some of 
our subjects that we did not include in our outcomes, the data indicated that these subjects 
had zero DNA content yet positive measurements for ALP and ARS. One explanation for 
this may be user error in the DNA extraction process. Another plausible explanation is 
that because the plate used for the DNA extraction was not the same plate used for the 
ALP and ARS assays, the measured DNA content was not representative of the true DNA 
content of the other plate. In the future, our aim is to develop a method for running all 
assays on the same plate to increase the accuracy of these measurements. Another 
limitation in our study was not counting ARS stained nodes under a microscope before 
using the acid extraction to quantify calcium. In the future we may continue to forgo 
counting nodules and possibly consider an alternative method to quantifying calcium 
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instead of the ARS stain and acid extraction. In the future, we also plan to measure total 
protein content, collagen content, and gene expression in RNA for a more comprehensive 
comparison between media supplemented with FBS and Mesencult-ACF. 
 
CONCLUSION 
 
In this study, we investigated the efficacy of both media supplemented with fetal 
bovine serum and serum-free, artificial media (Mesencult-ACF) to promote BMSC 
growth and differentiation. We found that both media conditions had similar growth and 
osteogenic differentiation potential overall. Our findings also highlighted the apparent 
inconsistency in DNA content and Alkaline Phosphatase content in media supplemented 
with FBS across subjects. The use of FBS in cell culture introduces a confounding 
variable to any set of data, and an alternative that does not include such confounders 
should be considered. Our findings suggest that Mesencult-ACF is a suitable alternative 
for the culture of BMSCs. Establishing a reliable method for BMSC cell culture is a 
crucial first step towards future studies aimed at evaluating the role of BMSCs in low 
bone mineral density and osteoporosis.  
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